Ibrutinib vs Clorambucilo-Burger-2015-e-pub

Burger Ja; Alessandra Tedeschi; Barr Pm; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Bartlett Nl; J. Li; David Simpson; Sebastian Grosicki; Stephen Devereux; H. McCarthy; Steven Coutré; Hang Quach; Gianluca Gaïdano; Zvenyslava Maslyak; Stevens Da; Ann Janssens; Fritz Offner; Julia M. Mayer; Michael O’Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Tam Cs; Michael J. Keating; T J Kipps; J. Jen; P. Jindra; Martin Šimkovič; A. Braester; Rosa Ruchlemer; R. Foà; Gianpietro Semenzato; T. Hawkins; Atanasio Cm; F. Demirkan; L. Kaynar; Halyna Pylypenko; Christopher P. Fox; Michael J. Thirman; Philip Campbell; P. Coughlin; Rosemary Harrup; Bryone J. Kuss; P. Turner; Wu Kl; Loree Larratt; Riva Fineman; Roberto Marasca; Pier Luigi Zinzani; Gillian Corbett; Pau Abrisqueta; Julio Delgado; Eva González‐Barca; de Oteyza; O. Arsland; Polina Kaplan; H. Oliynyk; Michael R Hamblin; J. Atkins; Jacqueline C. Barrientos; S. Gasic; Hou Jz; Edwin Kingsley; Mazyar Shadman; Xavier C. Badoux; Devinder Gill; Stephen Opat; Dominique Bron; Eric Van Den Neste; H. Jing; Jiang Zhu; Elisabeth Vandenberghe; Tamar Tadmor; Agostino Cortelezzi; Peter Ganly; Robert Weinkove; Andrzej Pluta; Alexander Pristupa; Marco Ja; F. Vural; Munchi Yagci; M. Kasych; Andrew Duncombe; Chris Fegan; R. Quackenbush; N. Tirumali

Article2018

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, David MacDonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Article2015

Benavides etal 2015 Survival vs growth trade-off in recruitment PPEES

Raquel Benavides, Adrián Escudero, Lluís Coll, Pablo Ferrandis, Fabrice Gouriveau, José A. Hódar, Romà Ogaya, Sonia G. Rabasa, Elena Granda, Blanca P. Santamaría, Jordi Martínez‐Vilalta, Regino Zamora, Josep María Espelta, Josep Penuelas, Fernando Valladares

Article2020

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen O. McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema,

Article2016

Changing Perceptions of Harm of E-Cigarettes Among U.S. Adults, 2012–2015

Ban Majeed, Scott R. Weaver, Kyle R. Gregory, Carrie Whitney, Paul Slovic, Terry F. Pechacek, Michael P. Eriksen

American Journal of Preventive Medicine

Article2022

IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

Jorge J. Castillo, Constantine S. Tam, Ramón García‐Sánz, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Alessandra Tedeschi, Tanya Siddiqi, Christian Buske, Véronique Leblond, Wai‐Yee Chan, Jingjing Schneider, Aileen Cohen, Meletios A Dimopoulos

Ibrutinib vs Clorambucilo-Burger-2015-e-pub

Discussion(0)

Related publications

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

Benavides etal 2015 Survival vs growth trade-off in recruitment PPEES

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Changing Perceptions of Harm of E-Cigarettes Among U.S. Adults, 2012–2015

IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia